Key Points
- Director William Waddill sold 8,367 shares on Dec. 19 at an average price of $67.65 for $566,027.55, reducing his stake by 12.89% to 56,563 shares (valued at about $3.83M).
- Multiple insiders sold shares in late December (including the CEO), which could pressure sentiment, although the CEO still retains a very large position.
- Analysts remain mostly positive — the consensus rating is "Moderate Buy" with an average target of $61.89 and several firms raising targets (up to $100); upcoming investor events (KOL webinar Jan 6 and JPM presentation Jan 12) could act as near-term catalysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director William Waddill sold 8,367 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.65, for a total transaction of $566,027.55. Following the completion of the transaction, the director directly owned 56,563 shares of the company's stock, valued at $3,826,486.95. This trade represents a 12.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Arrowhead Pharmaceuticals Price Performance
ARWR opened at $69.83 on Wednesday. The stock has a market cap of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. The company has a fifty day simple moving average of $49.81 and a 200 day simple moving average of $32.05.
Institutional Trading of Arrowhead Pharmaceuticals
Institutional investors have recently made changes to their positions in the business. Marex Group plc bought a new position in Arrowhead Pharmaceuticals in the second quarter valued at $576,000. Marshall Wace LLP grew its holdings in shares of Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock valued at $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. Moody Lynn & Lieberson LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $213,000. Norges Bank bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $30,414,000. Finally, CWM LLC boosted its position in Arrowhead Pharmaceuticals by 159.4% during the second quarter. CWM LLC now owns 11,415 shares of the biotechnology company's stock valued at $180,000 after purchasing an additional 7,014 shares during the last quarter. Institutional investors own 62.61% of the company's stock.
More Arrowhead Pharmaceuticals News
Here are the key news stories impacting Arrowhead Pharmaceuticals this week:
- Positive Sentiment: Company-scheduled investor activity in January could be a near-term catalyst: a KOL webinar on Jan 6 that will feature interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, plus a presentation at the J.P. Morgan Healthcare Conference on Jan 12. Favorable interim data or a well-received JPM presentation could boost sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
- Neutral Sentiment: Trading activity is below the stock’s average volume today, which can mute short-term moves; fundamental balance-sheet metrics remain strong (high current/quick ratios). No corporate guidance or major deals were announced.
- Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC filings and covered by press. Insider sales can be interpreted negatively by some investors even though the CEO retains a very large position (millions of shares) and reported reductions were small percentage changes in holdings. See SEC filings and press coverage for details. CEO Form 4 Director Form 4 Director Form 4 Director Form 4 Press: Insider Selling
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. HC Wainwright lifted their price objective on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a "buy" rating in a report on Tuesday, December 2nd. Piper Sandler lifted their price target on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday, December 17th. Bank of America upped their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a "buy" rating in a report on Tuesday, December 9th. Royal Bank Of Canada increased their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday, December 11th. Finally, Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 26th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $61.89.
Read Our Latest Research Report on ARWR
Arrowhead Pharmaceuticals Company Profile
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
